



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

December 15, 2022

Robert Ang, M.B.B.S.  
President and Chief Executive Officer  
Vor Biopharma Inc.  
100 Cambridgepark Drive, Suite 101  
Cambridge, MA 02140

**Re: Vor Biopharma Inc.**  
**Registration Statement on Form S-3**  
**Filed December 14, 2022**  
**File No. 333-268798**

Dear Robert Ang:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Jason Drory at 202-551-8342 with any questions.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences

cc: Divakar Gupta